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Research in context: Duchenne muscular dystrophy (DMD) is a severe muscle disease affecting 1:3500 male
births. DMD is caused by a mutation in dystrophin gene, coding for a protein required for skeletal and cardiac
muscle integrity. Lack of a functional dystrophin is primarily responsible for the muscle eccentric contraction-
induced muscle damage, observed in dystrophic muscle. However, inflammation plays a considerable role in
the progression of DMD. Glucocorticoids, which have anti-inflammatory properties, are being used to treat
DMD with some success; however, long term treatment with these drugs induces muscle atrophy and wasting,
outweighing their benefit. The identification of specific targets for anti-inflammatory therapies is one of the on-
going therapeutic options. Although blunting inflammation would not be a “cure” for the disease, the emerging
clue is that multiple strategies, addressing different aspects of the pathology, which may eventually converge,
may be successful. In this context, we previously showed that genetic ablation of Protein Kinase C θ (PKCθ), an
enzyme known to be involved in immune response, inmdx, the mousemodel of DMD, improves muscle healing
and regeneration, preventing massive inflammation. To establish whether pharmacological targeting of PKCθ in
DMD can be proposed as a therapeutic option, in this study we treated youngmdxmice with the PKCθ inhibitor
Compound 20 (C20). We show that C20 treatment led to a significant reduction in muscle damage associated
with reduced immune cells infiltration, reduced inflammatory pathways activation, and maintained muscle re-
generation. Importantly, C20 treatment is efficient in recoveringmuscle performance inmdxmice, by preserving
muscle integrity. Together, these results provide proof of principle that pharmacological inhibition of PKCθ in
DMD can be considered an attractive strategy to modulate immune response and prevent the progression of
the disease.
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DuchenneMuscular Dystrophy (DMD) is a severemuscle disease af-
fecting 1:3500 male births. DMD is caused by a mutation in dystrophin
gene, coding for a protein required for skeletal and cardiacmuscle integ-
rity (Mercuri andMuntoni, 2013;Muntoni, 2003;Muntoni et al., 2003).
Indeed, dystrophin is an essential component of the dystrophin glyco-
protein complex (DGC) which connects the extracellular matrix with
the intracellular actin filaments (Muntoni et al., 2003). Lack of a func-
tional dystrophin is primarily responsible for the muscle eccentric con-
traction-induced muscle damage, observed in dystrophic muscle
(Kumar et al., 2004). However, several alteredmechanisms are involved
in DMD onset and progression, resulting in muscle weakness and pro-
gressive muscle wasting (Evans et al., 2009a). Because of muscle dam-
age, cytokines expression is stimulated and immune cells infiltrate in
dystrophic muscle, contributing to worsen the dystrophic phenotype
(Evans et al., 2009b; Rosenberg et al., 2015; Villalta et al., 2015). Indeed,
dystrophic muscles are characterized by up-regulation of inflammatory
gene expression, such as NF-kB, and by an increase in inflammatory cell
infiltration, mostly composed by macrophages, neutrophils, and T cells.
Macrophages, neutrophils, and T cells are the primary cells that invade
the dystrophicmuscle. It is currently believed that neutrophils andmac-
rophages infiltrate the skeletal muscle around age 2weeks inmdxmice,
while CD8+ and CD4+ T cells infiltrate the muscle between age 4–
8 weeks (Evans et al., 2009a, 2010; Rosenberg et al., 2015). NF-kB path-
way results persistently activated in dystrophic muscle and it has been
proposed as one of themajor mediators of muscle wasting: it is activat-
ed prior the onset of the disease in response of increased Calcium influx
and mechanical stretch and it is responsible for the increased cytokine
expression and the immune response activation (Acharyya et al.,
2007; Kumar and Boriek, 2003; Messina et al., 2006, 2009). The repeat-
ed cycles of myofibers degeneration and regeneration, due to lack of
dystrophin, lead to the establishment of a chronic inflammatory envi-
ronment (Madaro andBouche, 2014). Thus, the functionalmuscle tissue
is replaced by a fibrotic and adipose non-functional connective tissue
(Kharraz et al., 2014; Pessina et al., 2015). Therapeutic strategies
based on the restoration of dystrophin expression or the administration
of dystrophin+ve stem cells are promising, but are often limited in effi-
cacy, and long-lasting efficacy has still to be reached (Bengtsson et al.,
2016; Cossu et al., 2015; Odom et al., 2011; Sampaolesi et al., 2003,
2006; Seto et al., 2012). The identification of specific targets for anti-in-
flammatory therapies is one of the ongoing therapeutic options. Al-
though blunting inflammation would not be a “cure” for the disease,
the emerging clue is that multiple strategies, addressing different as-
pects of the pathology,whichmay eventually converge,may be success-
ful. Glucocorticoids,whichhave anti-inflammatory properties, are being
used to treat DMD with some success; however, long term treatment
with these drugs induces muscle atrophy and wasting, outweighing
their benefit (Angelini, 2007; Angelini and Peterle, 2012; Schacke et
al., 2002; Schoepe et al., 2006). Numerous other anti-inflammatory
therapies, aimed to target more specific mediators of inflammation,
have been proposed to improve healing (Heier et al., 2013; Pelosi et
al., 2015). In this context, we previously showed that lack of PKCθ in
mdx, the mouse model of DMD, in the mdx/PKCθ−/−mouse model we
generated, was associated with reduced muscle wasting, improved
muscle regeneration and maintenance of performance compared to
mdxmice (Madaro et al., 2012).We further demonstrated, by bonemar-
row transplantation experiments, that PKCθ expression in immune cells
is required to mount a robust inflammatory response inmdx, which, in
turn, exacerbates the muscle pathology (Madaro et al., 2012). PKCθ be-
longs to the novel class of PKCs and is expressed in both hematopoietic
cells and in striated muscle (Marrocco et al., 2014; Nath and Isakov,
2014). In T cells, it is the key member of the PKC family to play a critical
role in the Ca2+/NFAT, AP-1 and NF-kB pathways to activate the IL-2
and IL-4 promoters, and it appears to be required for the development
of a robust inflammatory response in vivo (Pfeifhofer et al., 2003;Thuille et al., 2013; Wachowicz et al., 2014; Wachowicz and Baier,
2014; Kwon et al., 2012). Previous studies showed that PKCθ−/−mice
fail to develop experimental allergic encephalomyelitis, display drasti-
cally reduced lung inflammation after induction of allergic asthma,
and have a significantly diminished response in experimental colitis
and a type II collagen induced arthritis model (Anderson et al., 2006;
Fang et al., 2012; Tan et al., 2006; Wang et al., 2009). Of note, PKCθ−/−
mice may still mount a normal protective immune response to clear
viral infections (Giannoni et al., 2005), and maintain Treg function
(Gupta et al., 2008; Ma et al., 2012; Sun, 2012; Zanin-Zhorov et al.,
2010). Taken together, these evidences validate PKCθ as a particularly
attractive target to selectively manipulate Teff cell functions that are rel-
evant to pathogenesis of different diseases, including, as our results sug-
gested, muscular dystrophy. Noteworthy, a large effort is now devoted
to the synthesis of pharmacological PKCθ inhibitors, to be used for
anti-inflammatory therapies, and several PKCθ inhibitors have been
identified and reported in recent literature (Boschelli et al., 2010;
Chand et al., 2012; Curnock et al., 2014; Cywin et al., 2007; George et
al., 2015; Hage-Sleiman et al., 2015; Jimenez et al., 2013; Katoh et al.,
2016). Some of them bind selectively PKCθwhile others are non-selec-
tive in nature. One of the highly selective inhibitor for PKCθ reported
was C20, (compound 20 from Boheringer-Inglheim Pharmaceuticals,
Inc), belonging to the amino pyrimidine class of inhibitors (Cywin
et al., 2007; Sims et al., 2007; Zanin-Zhorov et al., 2010). In any case,
to propose a pharmacological protocol to inhibit PKCθ, eventual possible
effects on other tissues should be considered. Indeed, PKCθ is expressed
also in other tissue, including skeletal and cardiac muscle. In skeletal
muscle, we and others showed that PKCθ is mostly involved in mediat-
ing signaling pathways regulating fetal and early post-natal growth and
maturation (Madaro et al., 2011, 2013;Marrocco et al., 2014;Messina et
al., 2010; Zappelli et al., 1996). Employing PKCθ−/− mice, we also
showed that PKCθ maintains the correct structure and function of the
heart by preventing cardiomyocyte cell death in response to work de-
mand and to neuro-hormonal signals, to which heart cells are continu-
ously exposed (Paoletti et al., 2010).
Nevertheless, we already showed that genetic ablation of PKCθ in
mdx does not lead to apparent adverse effects, while it significantly
ameliorates the progression of the disease, preventing a robust inflam-
matory response (Madaro et al., 2012). In this study, we show that in
vivo pharmacological inhibition of PKCθ inmdxmice significantly ame-
liorates the dystrophic phenotype, at bothmorphological and functional
levels.
2. Materials and Methods
2.1. Animal Models
Mdxmice (C57BL/10ScSn-Dmdmdx/J) were purchased from Jackson
laboratory and mdxPKCθ−/− transgenic mice were generated in our
laboratory (C57BL/6j-C57BL/10ScSn background). C57BL/10ScSn con-
trol mice (WT mice) were purchased from Jackson laboratory. Only
males were used. The animals were housed in the Histology Depart-
ment–accredited animal facility. All the procedures were approved by
the Italian Ministry for Health and were conducted according to the
U.S. National Institutes of Health (NIH) guidelines.
2.2. Compound 20 and In vivo Treatment
The PKCθ-specific inhibitor compound 20 (C20)was gently provided
by Dr. Maryanne Brown (Boehringer Ingelheim Pharmaceuticals Inc.,
Ridgefield, CT, USA) (Cywin et al., 2007). Pharmacokinetics (PK) data
are summarized in Fig. S1, and show that C20 has a good in vivo activity
with oral delivery in T cell mediated models. Oral delivery is usually
harder than intra-peritoneal, to get a decent exposure. The rat PK data
is complete and the mouse exposure is similar to rat levels at 2.5 h
(M. Brown, personal communication)
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peritoneally injected with 10 mg/kg C20 or vehicle (10% DMSO is phys-
iological solution) for 2 weeks. At the end of treatment, at age 6 week,
themice were sacrificed and themuscles were analyzed at bothmolec-
ular and histological level.
To induce muscle atrophy by food deprivation, mice were main-
tained for 24 h, starting early in the morning the day before being
sacrificed, with no food but free access to water (Madaro et al., 2013).
2.3. Concanavalin A (ConA) Induced IL-2 Production and ELISA Assay
WT mice were pre-treated, with a single intra-peritoneal (IP) 5 or
10 mg/kg dose of C20, or with the vehicle alone; in parallel, a group of
WT mice was pre-treated with 30 mg/kg Cyclosporine A (CsA)
(Sigma-Aldrich, Saint Louis, MO, USA), as control. After 1 h following
pre-treatment with C20 or CsA, mice were intravenously injected with
a single dose of 8 mg/kg ConA (Sigma-Aldrich). In parallel, a group of
PKCθ−/− mice was also treated with the ConA or with the vehicle
(10% DMSO in physiologic solution). After 2 h, the mice were bled via
cardiac puncture and sera were analyzed for IL-2 production by ELISA.
For the IL-2 quantification in serum, a Mouse Interleukin-2 ELISA kit
(Thermo Scientific™, Waltham, MA, USA) was used, following the
manufacturer's protocol. The kit is very sensitive (b3 pg/ml) and it has
a good reproducibility (intra-assay variability b10%). The absorbance
was measured on a plate reader at 550 nm.
2.4. Antibodies
The following antibodies were used: the anti-p-NFκB p65 (Ser536)
(clone 9H31) and the anti-NFκB p65 (clone C22B4) from Cell Signaling
Technology (Danvers,MA, USA); the anti-Gapdh (clone6C5) fromSanta
Cruz Biotechnology (Dallas, Texas, USA); the anti-embryonic Myosin
Heavy Chain, eMyHC (clone F1.652) from Developmental Studies Hy-
bridoma Bank (Iowa City, IA, USA); polyclonal anti-Laminin from
Sigma-Aldrich; the anti-CD45 PE/Cy5 conjugated (clone 30-F11) from
BD Pharmigen™ (San Jose, CA, USA); the anti-CD31 Alexa Fluor 488
conjugated (clone MEC13.3) from Biolegend (San Diego, CA, USA); the
anti-mouse IgG TRITC conjugated and the anti-rabbit IgG TRITC con-
jugated from Sigma Aldrich; the anti-mouse IgG Alexa Fluor 488
conjugated from Invitrogen; the anti-rabbit IgG Chromeo 488 conju-
gated from Abcam (Cambridge, MA, USA); the anti-mouse IgG and
the anti-rabbit IgG HRP conjugated from Bethyl Laboratories
(Montgomery, TX, USA).
2.5. Western Blotting
For total protein extract preparation, GAmuscles derived from vehi-
cle and C20 treatedmdxmicewere homogenized in ice-cold buffer con-
taining 20mMTris (pH 7.5), 2mMEDTA, 2mMEGTA, 250mM sucrose,
5 mM DTT, 200 mg/ml leupeptin, 10 mg/ml Trasylol, 1 mM PMSF, and
0.1% Triton X-100 and then disrupted by sonication. The homogenate
was incubated for 30 min on ice with repeated vortexing, then centri-
fuged at 12,000g for 10min at 4 °C. The pellet was discarded. An aliquotFig. 1. In vivo C20 treatment prevents T cell activation and does not alter skeletalmuscle and hea
with C20 (5 or 10 mg/kg) or with Cyclosporin (CsA, 30 mg/kg), or vehicle-treated, as indicated
shown. Statistical significancewas determined by a one-wayANOVA using aDunnett's post-test
observed between the twodoses of C20was not significant. B.Morphological analysis of TAmus
for Laminin in TA muscle cryosections from vehicle- or C20-treated WT mice, as indicated (b
vehicle- (black bars) or C20- (grey bars) treated WT mice; the percentage of fibers within th
deprivation-induced muscle atrophy in WT mice treated or not with C20. Upper panel: body w
fasted (dotted bars) conditions, as indicated. Lower panel: frequency distribution of the fibers
or not (black dotted bars) with C20, as indicated. D. Analysis of the heart in WT mice treated
WT mice treated or not treated with C20, as indicated. Lower panel: Real Time PCR analysis of
as indicated; the level of expression in hearts from age-matched PKCθ−/−mice is also shown
used to normalize the values. Statistical significance was determined by Student's t-test (*, p bof the supernatants was used for protein determination using the
Comassie Plus protein assay reagent (Pierce, Rockford, IL), according
to the manufacturer's instruction, while the remainder was used for
Western blot analysis. An equal amount of protein from each sample
was loaded onto 10% SDS-polyacrylamide gel and transferred to a nitro-
cellulose membrane (Schleicher and Schuell, Dassel, Germany). The
membranes were incubated with the appropriate primary and second-
ary antibodies, and processed as previously described (Madaro et al.,
2011). Densitometric analysis was performed using the Image J soft-
ware (NIH, Bethesda, MA, USA).
2.6. Flow Cytometry
For FACS analysis, Gastrocnemius muscles (GA) from mdx mice,
treated with the vehicle and with the C20, were collected and then
digestedwith Collagenase type IV for 1 h and 30′ at 37 °Cwith agitation.
The cells were passed through a 70 μm and then a 40 μm cell strainer,
centrifuged at 1200 rpm and suspended in 100 μl of 1% FBS in PBS
(phosphate buffered saline). The cells were stained with the CD45 PE/
Cy5 antibody (clone 30-F11 from Pharmigen TM) and with DAPI and
then analyzed by the FacsStar Plus cytofluorimeter.
2.7. Histological and Immunofluorescence Analyses
Individual limb muscles (Tibialis Anterior, TA, and GA), Diaphragm
(DIA) and heart were dissected. Thereafter, cryosections were prepared
for histological and immunohistochemical analyses. Sections stained
with hematoxylin/eosin or with Masson's trichrome stain (both from
Sigma-Aldrich) were photographed and the images were analyzed
using Image J. Cross sections of the TA muscle around its mid-portion
were used to measure muscle cross sectional area. The total number of
myofibers was also counted, as well as the number of myofibers per
square millimeter. For immunohistochemistry, crysections were fixed
in 4% paraformaldehyde (Sigma-Aldrich) at room temperature (RT)
and then incubatedwith PBS containing 1% BSA for 15min at RT, before
being incubated with PBS containing 5% goat serum for 30 min at RT.
The cryosections were then incubated overnight at 4 °Cwith the appro-
priate primary antibodies. The day after theywere washedwith PBS, in-
cubated for 15min with 1% BSA in PBS, and then incubated for 1 h with
fluorochrome-labeled secondary antibodies and Hoechst 33342 (Fluka)
for nuclear staining. After extensive washing with PBS, the slides were
mounted in 10 mM Tris-HCl, pH 9.00, containing 60% glycerol, and ex-
amined in a Zeiss Axioskop 2 Plus fluorescence microscope.
Themuscle fibermean cross sectional area (CSA)was determined by
immuno-staining for α-laminin and measuring CSA of fibers in the en-
tire section, using the macro for Image J for automatic fiber CSA assess-
ment. Myofiber variability was determined bymultiplying the standard
deviation of all measurements by 1000 and dividing it by themeanfiber
diameter (Madaro et al., 2012). IgG immune-staining was used to iden-
tify damaged myofibers while eMyHC (embryonic Myosin Heavy
Chain) was used to identify regenerating myofibers (Madaro et al.,
2012). The extent of the area containing IgG- or eMyHC-positive
myofibers was measured by Image J in 3 different GA sections/mouse.rt functions. A. ELISA assay of IL-2 serum level in ConA treatedWTmice, pre-treated or not
. IL-2 serum level in untreated WT and in PKCθ−/−mice treated or not with ConA, is also
(*, p b 0,05;means±STDEV; n=3 for each group). Themild difference in IL-2 production
cle inWTmice treated or not treatedwith C20. Upper panel: immunofluorescence analysis
ar = 400 μm); Lower panel: cross sectional area (CSA) fiber distribution in TA muscle of
e given range of CSA is indicated for each group of mice (n = 3 mice per group). C. Food
eight of WT mice treated (grey bars) or not (black bars) with C20, in fed (plain bars) or
CSA in TA muscle derived fromWT fed (black bars) or fasted treated (grey dotted bars)
or not with C20. Upper panel: Masson's Trichrome staining of crysections of heart from
ANP, βMyHC and TGFβ expression level in hearts from vehicle- or C20-treated WT mice,
(*, p b 0,05; means ± STDEV; n = 3 mice for each group). Gapdh level of expression was
0.05; means ± STDEV; n = 5 mice per group).
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total area of the section. The average from the three different sections/
mouse was calculated and plotted on the graph.
2.8. Exhaustion Treadmill Test
The analyses were carried out using a five-lane motorized treadmill
(LE 8710, PanLab S.L.U., Barcelona, Spain) supplied with shocker plates.
Mice were first acclimated to the treadmill by making them run 20 min
at 6 m/min the day before the beginning of the test (at day -1). In the
protocol used, the treadmill was run at an inclination of 0° at 8 cm/s
for 5 min, after which the speed was increased by 2 cm/s every min.
The test was stopped when the mouse remained on the shocker
plate for N20 s without attempting to reengage the treadmill. The
time to exhaustion was determined from the beginning of the test.
Three tests were performed on the same animal, once per week.
All the cohorts run together and all the different groups were done
at the same time.
2.9. Muscle Functional Studies Ex vivo
Extensor digitorum longus (EDL) muscles were vertically mounted
in a temperature controlled (30 °C) chamber containing Krebs Ringer
bicarbonate buffer (Sigma K-4002) continuously gassed with a mixture
of 95% O2 and 5% CO2 (pH 7.3 ± 0.3; osmolarity: 267 ± 5% mOsm/L).
One end of the muscle was linked to a fixed clamp while the other
end was connected to a force transducer (Aurora Scientific Instruments
300B). EDL muscles were electrically stimulated by means of two plati-
num electrodes with 300 mA controlled current pulses (Del Prete et al.,
2008). To evaluate the decline of force, 5 tetanic stimulations were im-
posed to the muscle with a recovery period of 2 min between each of
them (Pelosi et al., 2007). The maximum force was measured from the
first tetanic stimulation. The Muscle CSA was calculated dividing the
musclemass by the product of Lf and the density ofmammalian skeletal
muscle (1.06mg/mm3). Lf is the optimal fiber length and is obtained by
multiplying the muscle length (L0) to the fiber length ratio, which is
0.44 for EDL muscle.
2.10. RNA Extraction and Quantitative Real Time PCR
Total RNA from muscle tissues was extracted using the TRIsureTM
(Bioline, London, UK), converted in cDNA using the High-Capacity
cDNA-RT kit fromApplied Biosystem, according to supplier's instructions.
PCR amplification was performed using the Euroclone FluoCycle™ II
SYBR® Green, following the manufacturer's protocol. For data analysis,
the 7500 Software v2.0.5, provided by Applied Biosystem, was used. All
PCR reactions were carried out in triplicate (duplicate for the standard
curves). All qPCR results are expressed as relative ratios of the target
cDNA transcripts toβ-actin and normalized to that of the reference condi-
tion. The following primers were used for amplification: ANP-for TGG
GAC CCC TCC GAT AGA TC; ANP-rev AGC GAG CAG AGC CCT CAG T;
βMyHC-for TCT CCT GCT GTT TCC TTA CT; βMyHC-rev GTA CTC CTC
TGC TGA GGC TT; TGFβ-for GGATACCAACTATTGCTTCAGCTCC; TGFβ-rev
AGGCTCCAAATATAGGGGCAGGGTC; eMyHC-for TCGTCTCGCTTTGGCAA;
eMyHC-rev AGCAGCTCAATCAGCTCA.Fig. 2. C20 treatment prevents damage and inflammation in dystrophic muscles. A. Hematoxyl
(b), or with the vehicle (a), the last twoweeks. The asterisk indicatesmyonecrosis area and arro
and d) in serial cryosections as in a and b, respectively. The extend of IgG positive area over the
used for quantification, and expressed as the average measured in three different sections/mou
Western blot analysis of NFκB (p65) expression and phosphorylation in total protein extract of G
pNFκB/NFκB is shown in the right as revealed by densitometric analysis. C. Representative ima
C20 (b) treatedmdxmice. Hoechst (blue) was used to visualise the nuclei. (Bar = 400 μm). (c
from vehicle- (left plot) or C20- (right plot) treatedmdxmice; (d) cytofluorimetric analysis of C
mice (*p b 0,05; means ± STDEV; n = 8/9 mice/group). Statistical significance was determine2.11. Statistical Analysis
Quantitative data are presented asmeans±SDof at least threemice,
as indicated for each experiment. Statistical analysis to determine
significance was performed using paired Student's t-tests or with
ANOVA test. Differences were considered statistically significant at the
p b 0.05 level.
3. Results
3.1. In vivo C20 Treatment Prevents T Cell Activation but Does Not Alter
Skeletal Muscle and Heart Functions
In preliminary studies,we tested the ability of the PKCθ inhibitor C20
to prevent Concanavalin A (ConA)-induced T cell activation in vivo in
C57BL/10ScSn WT mice. ConA is a well-known T cell mitogen and,
since PKCθ is an essential factor promoting T cells activation and prolif-
eration, its lack/inhibition should prevent ConA-induced T-cell prolifer-
ation and IL2 production. As shown in Fig. 1A, ConA treatment induced
high level of serum IL-2 compared to the untreated. As expected, Cyclo-
sporine (CsA) pre-treatment, a well-known immune-suppressor,
abolished ConA-induced serum IL-2. C20 pre-treatment, at both 5 and
10mg/kg doses, also abolished ConA-induced IL-2 production, at similar
level as CsA. Lack of PKCθ in PKCθ−/− mice also prevented ConA-in-
duced IL-2 production, as it did C20 treatment.
Further, we investigated whether C20 treatment may results in detri-
mental effects in skeletal and cardiacmuscle homeostasis and activity.We
used 4-week-old C57BL/10ScSn WT mice for these analyses. We choose
this age because it is still a reasonably young age inmdx tomake the treat-
ment effective, and, on the other hand, a reasonably old age to prevent
eventual adverse effect in skeletal muscle growth. In fact, PKCθ expres-
sion/activity is required mostly during the early stages of skeletal muscle
development, up to 4–5weeks of age, and its lack/inhibition at these early
stages may interfere with muscle growth (Madaro et al., 2011). Four-
week-old WT mice were IP injected with the C20 daily for 2 weeks,
after which the mice were sacrificed and weighted. TA muscles and
heart were then dissected, weighted and analyzed for morphological
and molecular features. No differences in body weight were detected in
mice treated with C20 compared to the untreated ones (Supplemental
Fig. S2). Intriguingly, an increase in TA muscle weight, normalized to
body weight, was observed in C20 treated mice compared to untreated
(Supplemental Fig. S2). However, myofibers CSA, measured in all the fi-
bers of the entire section, was similar in TA derived from C20-treated
mice and untreated (Fig. 1B). Moreover, C20 treatment did not alter the
ability of muscle to adapt to external stimuli, such as fasting (Fig. 1C). In-
deed,wepreviously demonstrated that lack of PKCθ, in the PKCθ−/−mice,
prevented fasting-induced atrophy in skeletal muscle (Madaro et al.,
2013), thus we also wondered whether PKCθ acute inhibition may alter
this response. Six-week-old WT mice were treated with C20 (10 mg/kg)
for 2 weeks, and foodwas removed for the last 24 h, to inducemuscle at-
rophy. We choose this age because it was the age of the mice used in the
previous study. The mice were sacrificed and analyzed for body weight
andmyofiber CSA. As shown in Fig. 1C, after 24 h of starvation, C20-treat-
ed and vehicle-treated mice showed similar reduction in body weight,
and similar distribution of myofiber CSA in TA muscle (Fig. 1C). In-
terestingly, the observed increase in TA muscle weight might bein/Eosin staining (a and b) of GAmuscles from 6-week-oldmdxmice treated with the C20
w indicates inflammatory area. Double immunofluorescence analysis of IgG and laminin (c
total area of GAmuscle section from each individual is shown in e. The entire muscle was
se; each dot represents a single mouse. (Bar = 400 μm (a and b); =200 μm (c and d). B.
Amuscles derived fromvehicle and C20 treatedmdxmice, as indicated; the ratio between
ge of CD45 (red) immunofluorescence staining of GA muscle section from vehicle (a) and
) Representative picture of cytofluorimetric analysis of CD45+ cells in GA muscles derived
D45+ cells in GAmuscles derived from C20- (grey bar) or vehicle- (black bar) treatedmdx
d by Student's t-test.
155V. Marrocco et al. / EBioMedicine 16 (2017) 150–161accounted for the increase in myofibers number. In fact, we found
that also TA muscle CSA was increased due to increase in the num-
ber of myofibers (Supplemental Fig. S2). Together, these results
demonstrate that C20 treatment does not alter limb musclemorphology and function, rather it induces increased muscle mass
and myofiber number.
In addition, an increase in heart weight, normalized to body weight,
was also observed in C20-treated mice compared to untreated
Fig. 3. C20 treatment improves muscle regeneration in 6-week-old mdx mice. A. Immunofluorescence analysis of eMyHC (red) expression in GA muscle cryosections derived frommdxmice
treatedwith theC20 (b) orwith thevehicle (a). Representative images are shown.Hoechst (blue)was used to visualise thenuclei. (Bar=400 μm). (c)Ratio of eMyHC+ve area over the total area
of each section. The entire section was used for quantification, and three sections/mouse were averaged; each dot represents a single mouse. Statistical significance was determined by the
Student's t-test. (*, p b 0,05; means ± SEM; n = 8/9 mice/group). B. Real Time PCR analysis of eMyHC level of expression in vehicle- and C20-treated mdx mice, as indicated. C.
Immunofluorescence analysis of CD31 expression in GA muscle cryosections derived from WT (a) mdx mice treated with the C20 (c) or with the vehicle (b) (Bar = 200 μm). (d) The
number of capillaries/fiber was determined in each mouse; at least 3 sections per muscle were used for quantification. Statistical significance was determined by a one-way ANOVA using a
Dunnett's post-test. (*, p b 0,05; means ± SEM; n = 4mice/group).
156 V. Marrocco et al. / EBioMedicine 16 (2017) 150–161(Supplemental Fig. S2). However, no alterations in cardiacmuscle struc-
ture or deposition of collagen was observed, nor in the expression of
genes involved in pathological LV remodeling or fibrosis (Fig. 1D). We
previously showed that lack of PKCθ results in increased fibrosis and ex-
pression of AtriumNatriuretic Peptide (ANP), β-Myosin heavy chain (β-
MyHC) and transforming growth factor β (TGFβ) in 8-week-old mice
(Paoletti et al., 2010). As shown in Fig. 1D, no fibrosis was detected in
heart derived from both untreated or C20-treated mice. Accordingly,the expression of ANP, β-MyHC and TGFβwas similar in hearts derived
from untreated and C20 treated mice. Conversely, ANP expression was
significantly induced in hearts derived from 6-week old PKCθ−/−
mice, as expected.
Together, these data demonstrate that C20 treatment in vivo is effec-
tive in inhibiting T cell activation, and that 2week C20 treatment has no
apparent detrimental effects on both skeletal and cardiac muscle
homeostasis and maintenance.
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Muscles
Next, four-week-old mdx mice were treated with 10 mg/kg C20 or
with the vehicle for 2 weeks. After treatment, mice (6-week-old) were
sacrificed and myofiber degeneration was evaluated in cryosections of
GA muscle by IgG staining. As shown in Fig. 2A, significant reduction
in the extension of the area including degenerating myofibers was
observed in GA muscles derived from the mice treated with the C20,
compared to the vehicle-treated mice (Fig. 2A).
We then verified whether the reduced muscle damage observed in
C20-treatedmdxmicemight depend, at least in part, on reduced inflam-
matory response, since the primary cause of the disease, that is lack of
dystrophin, was not removed. Western blot analysis revealed that the
high level of phosphorylation/activation of the inflammation-associated
factor NFκB, observed inmuscle of vehicle-treatedmdxmice,was signif-
icantly reduced inmuscle of C20-treatedmdxmice (Fig. 2B). Of note, re-
duced extension of the area containing infiltrated inflammatory
CD45+ve cells was observed by immunofluorescence in muscle from
C20-treated mice compared to vehicle-treated (Fig. 2C). FACS analysis
revealed a 20% reduction of CD45+ve cells in mononucleated cells
isolated from muscle of C20-treated mice compared to vehicle-
treated (Fig. 2C).Fig. 4. C20 treatment prevents the drop-in force observed in muscle frommdxmice ex vivo. A
Specific Force, generated by of EDL muscles as in A, obtained as the ratio of the Fmax genera
measured from the first tetanic stimulation of EDL muscles fromWT mice and mdxmice treat
each muscle and the ratio between them (Fmax/CSA). (*p b 0,05 was obtained comparing Fm
group). D. The drop-in force, evaluated as the value of force developed during the last stimu
(*p b 0,05, means ± STDEV; n = 5 for each group). E. Force developed by EDL muscles fromW
line), during repeated stimulations, as indicated. The value determined in each stimulati
stimulation, and assumed as 100. Statistical significance was determined by TwoWay ANOVA t3.3. C20 Treatment Boosts Muscle Regeneration in mdx Mice
Muscle regeneration was then analyzed in GAmuscles derived from
mdxmice treated or not treated with C20, as above, by immunoflu-
orescence for the expression of eMyHC. As shown in Fig. 3A, the ex-
tent of area including regenerating myofibers was similar in muscle
derived from C20 treated mdx mice, compared to the vehicle-treated.
qRT-PCR analysis confirmed that the level of expression of eMyHC
was similar in muscle derived from C20-treated mdx mice and un-
treated (Fig. 3B).
Since we observed less damage in C20-treated muscle than in vehi-
cle-treated (Fig. 2), but muscle regeneration was similar, this fact im-
plies that the ratio between the damaged and the regenerated area is
lower in C20-treated muscle compared to vehicle-treated, suggesting
that muscle regeneration is boosted by C20 treatment. However, C20
treatment does notmodify themyofibers CSA, nor variability coefficient
or the ratio of centro-nucleated vs peripheral nucleatedmyofibers (Sup-
plemental Fig. S3).
Since reduced capillarity in muscles from mdxmice was previously
described as a result of necrosis-induced muscle ischemia (Palladino
et al., 2013), we then counted the number of capillaries in GA muscles
from C20-treated and untreatedmdxmice. In line with the observation
of boosted regeneration, the number of capillaries was higher inmuscle. CSA of EDL muscles derived from 6-week old WT, vehicle- or C20-treatedmdxmice; B.
ted following the first stimulation/CSA; D. Table including: the maximum force (Fmax)
ed with the vehicle and with C20, as indicated; the muscle cross sectional area (CSA) for
ax/CSA from WT to both vehicle- or C20-treated mdx; means ± STDEV; n = 5 for each
lation (F5) divided for the initial value of force (F1), expressed as percentage: F5/F1%.
T (dotted line) andmdxmice treated with the C20 (grey line) or with the vehicle (black
on is expressed as the percentage to the value obtained from each group at the first
est with Tukey's multiple comparisons (*p b 0,05, means± STDEV; n= 5 for each group).
Fig. 5. C20 ameliorates fatigue resistant and protects muscle from degeneration after a treadmill assay. A. Exhaustion Treadmill test performed on vehicle (black line) and C20 (grey line)
treatedmdxmice;WTmice (dotted line)were also used for comparison (n=5 each group).Muscle strengthwasmeasured as duration (a) or distance (b) to exhaustion,measured 7 (T1)
and 14 (Tf) days after the beginning of the treatment; the obtained values are expressed as percentage in respect to the values measured at the beginning of the treatment (T0). B. The
values of treadmill duration (a) and distance (b) of WT andmdx treated with the vehicle and with the C20 at different time points during the treatment are reported in tables c and d,
respectively. C. Representative images of Hematoxylin/Eosin (a and b) or of the IgG and Laminin double immunofluorescence analysis (c and d) of GA muscle cryosections derived
from C20- or vehicle-treated mdx mice, as indicated, and subjected to treadmill exercise. GA muscles were harvested at the end of the treadmill test, (Tf), as in A. (Bar = 400 μm (a
and b); =200 μm (c and d)). The asterisk indicates myonecrosis area and arrow indicates inflammatory area. The ratio between the area positive for IgG (as sign of necrosis) over the
total area of muscle section from exercised C20- or vehicle-treated mdx mice is shown in e. At least 3 sections per muscle were used for quantification. Statistical significance was
determined by Student's t-test. D. Same as in C, but in DIA muscle from the same mice (means ± STDEV; n = 5 for each group). *Significantly different (p b 0.05) from vehicle and #
significantly different fromWT.
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mdx mice, and was similar to that counted in GA muscles from age-
matched WT mice (Fig. 3C).3.4. C20 Treatment Prevents the Drop-in Force Observed in Muscle From
mdx Mice Ex vivo
We then verified whether C20 treatment may improve dystrophic
muscle contraction activity. In fact, although lack of dystrophin primar-
ily leads to muscle contraction defects, inflammation and fibrosis con-
tribute to worsen the muscle weakness in dystrophic mice and in
DMD patients. EDL muscle was dissected from WT, vehicle- or C20-
treated mdx mice and analyzed ex vivo for contractile parameters. As
expected, a significant reduction of the Fmax generated frommuscle de-
rived from vehicle-treated mdx mice was observed compared to WT.C20 treatment partially rescued the observed reduction in terms of ab-
solute generated Fmax (Fig. 4A). However, in linewithwhat observed in
TA muscle, we found that muscle CSA was higher in EDL derived from
C20-treated mdx mice compared to mdx; thus, the specific force
(Fmax/CSA) generated remained unaltered (Fig. 4A). Conversely, a sig-
nificant reduction in force drop ofmuscle derived fromC20-treatedmdx
mice, compared to untreated mdx, was found (Fig. 4B). Notably, the
force produced by EDL muscle derived from untreated mdx mice de-
creased after each stimulation, presumably because of muscle damage,
starting from the third stimulation., After 5 consecutive stimulations,
the force generated by EDL derived from untreated mdx muscles
(Fmax5) was reduced of about 25% compared to the initial one
(Fmax1). By contrast, the force produced by EDL derived from C20-
treated mdxmice was maintained almost unaltered between the first
and the last stimulation, similarly to what observed in muscle derived
fromWTmice (Fig. 4).
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Next, we evaluated performance of C20- or vehicle-treated mdx
mice in a fatigue resistance protocol on a treadmill, during the treat-
ment. A group of WT mice was also included. Distance to exhaustion
and time to exhaustion were measured for each mouse at day 7 and
14 during C20 treatment, and was compared to the day 0 values. As
shown in Fig. 5A, the initial treadmill duration, at T0, was similar in all
group of mice (WT, vehicle-, or C20-treated mdx). The initial distance,
at T0, run by WT and vehicle-treatedmdxmice was also similar, while
the one run by the C20-treated mdx mice appeared greater, although
this difference was not significant. Both time to exhaustion and dis-
tance, run by WT mice, at day 7 (T1) and 14 (Tf) remained unaltered.
By contrast, both duration and distance was significantly reduced in ve-
hicle-treatedmdxmice at T1, and further at Tf: they covered on average
a shorter distance and became exhausted much faster, compared toWT
(Fig. 5A). Interestingly, C20-treatedmdxmice covered on average a lon-
ger distance in comparison to their untreated counterparts, already at
T1, as well as at Tf. Also, C20-treated mdx mice became exhausted
much slower at both T1 and T2, compared to vehicle-treated mdx
mice (Fig. 5A)
Since susceptibility to the exhaustion training inmdxmice might be
primarily due to exercise-inducedmuscle damage, due to the absence to
dystrophin, we next evaluated morphology of muscle derived from
exercised mice. As shown by H/E and IgG staining, both GA and DIA
muscles derived from exercisedmdxmice were dramatically damaged,
and many IgG stained necrotic fibers were observed. By contrast, C20
treatment preserved muscle integrity after training, in both GA and
DIA, counteracting the muscle damage observed in untreated mdx
mice (Fig. 5B). Together, these results demonstrate that acute inhibition
of PKCθ is very efficient in recovering muscle performance in mdx, by
preserving muscle integrity.
4. Discussion
This study demonstrates that pharmacological inhibition of PKCθ in
4-week-old mdx mice, significantly prevents muscle wasting and
inflammatory response, while maintains muscle regeneration and
improves function and performance.We used the C20, one of the previ-
ously identified potent and selective PKCθ inhibitors (Cywin et al.,
2007), and show that in vivo C20 treatment prevented ConA-induced
T cells activation, as expected for a PKCθ inhibitor (Bermejo et al.,
2015; Cywin et al., 2007; Zanin-Zhorov et al., 2010). Although its even-
tual clinical application should be further investigated, our data provide
proof of principle that pharmacological targeting of PKCθ in muscular
dystrophy would be effective in ameliorating the disease, as our previ-
ous genetic studies suggested. We show that two week C20 treatment
of 4-week-old mdx mice significantly reduced histo-pathological fea-
tures of dystrophic muscle. We decided to treatmdxmice at 4 week of
age, when immune cells are infiltrating muscle, thus, if our hypothesis
was correct, we would expect that C20 treatment should prevent/re-
duce inflammatory response. On the other hand, previous studies
have demonstrated that PKCθ expression/activity is required for com-
plete histogenesis, differentiation and homeostasis of skeletal muscle,
as well as for cardiomyocyte survival and remodeling (Camerino et al.,
2014; Madaro et al., 2011; Messina et al., 2010; Paoletti et al., 2010;
Tokugawa et al., 2009; Zappelli et al., 1996). We already showed that
in a context of chronic inflammation, where immune cells activity is a
key determinant, as inmuscular dystrophy, lack of PKCθ predominantly
affects immune response ameliorating the disease, and no obvious ad-
verse effects were observed in other tissues (i.e. skeletal and cardiac
muscle) (Madaro et al., 2012). We show here that C20 treatment of 4-
week-oldWTmice, did not result in deleterious effects on either skeletal
or cardiac muscle phenotype, nor on the ability of skeletal muscle to re-
spond to external stimuli, as to fasting; however, increased skeletal and
cardiacmusclemasswas observed. In TAmuscle this is possibly due to arise in the number of myofibers, as we observed, which might be
beneficial in a context of muscle wasting; although the underlying
mechanism(s) is not clear yet, it may explain the boostedmuscle regen-
erative ability, observed in C20-treated dystrophic mice. In fact, we did
not observe myofiber number increase in TA derived from C20-treated
mdxmice, and the percentage of centrally and peripherally nucleated
myofiberwas unaltered. However, sincemyofiber damagewas reduced,
compared to muscle from untreated mdxmice, as discussed below, the
maintenance of muscle regeneration might be due to increase in satel-
lite cells activation and myogenesis, in line with the C20-induced fiber
number increase in WT muscle. Besides, we showed that 2 week C20
treatment of 4-week-old mdx mice, significantly reduced muscle fiber
degeneration, immune cells infiltration, as well as inflammatory path-
ways activation, such as NFκB. Indeed, NFκB is activated very early in
muscle from mdx mice, probably because of contraction-induced
muscle injury. NFκB is known to regulate the expression of many
inflammatory genes, including cytokines and chemokines in both
immune cells and muscle fibers, thus maintaining an inflammatory
environment.
Interestingly, despite the reduced muscle damage, the level of mus-
cle regeneration was similar in C20-treated and untreatedmdxmice, as
shown by the extent of the area including eMyHC expressing fibers. It is
generally accepted that the level of muscle regeneration should be pro-
portional to the level of damage, since it is activated to replace damaged
fibers. However, in DMD muscle progenitor cells activation/differentia-
tion is limited, mainly due to the exhaustion of muscle progenitor cells
pool, given the continuous cycles of degeneration/regeneration, but
also chronic inflammation contributes to make an unfavorable environ-
ment for their activation/differentiation. The fact that C20 treatment, as
well as PKCθ genetic ablation (Madaro et al., 2012) reduces muscle
damage but maintains muscle regeneration in mdx, suggests that the
treatment makes a more favorable environment for muscle precursors
cells to differentiate by reducing inflammation and thus allowing mus-
cle repair, a possibility which is being further investigated. Moreover, as
suggested here, C20 treatment may increase myofibers number in WT
muscle, ability thatmay contribute to themaintenance ofmuscle regen-
eration in dystrophic muscle.
Importantly, C20 treatment significantly improvedmuscle function-
ality both ex vivo and in vivo, and preserved muscle from contraction-
induced muscle damage. We showed that although the force generated
from EDL muscle derived from C20-treated mdxmice was higher than
that from untreated, the specific force was similar. However, a signifi-
cant reduction in force drop of muscle derived from C20-treated mdx
mice, compared to untreated mdxwas observed. This fact might imply
that muscle integrity is maintained by C20 treatment, making it more
resistant to the subsequent contractions, as observed following the ex-
haustion treadmill assay. On the other hand, the eventual improved
blood supply might also prevent loss of force, thus contributing to resis-
tance. Accordingly, C20-treatedmdxmice performed much better than
untreated mdx littermates in an exhaustion treadmill assay, probably
because of the maintenance of muscle integrity. In fact, we show that
the expected muscle damage observed in exercised mdxmice was sig-
nificantly prevented by C20 treatment. These resultswere quite surpris-
ing since dystrophin is lacking in C20-treated mice, as well. It is
conceivable that C20 treatment, reducing the inflammatory response,
created a qualitative environment that makes the dystrophic muscle
more resistant to the damage exerted by mechanical contraction, as it
was observed also whenmdxmice were treated with anti-IL6 antibody
(Pelosi et al., 2015)
Our findings make PKCθ a very attractive target to counteract
Duchenne Muscular Dystrophy and provide proof of principle that its
pharmacological inhibition in DMD can be proposed in order to coun-
teract the disease, as long as specific and selective PKCθ inhibitors,
with a defined therapeutic profile will be characterized. Moreover, the
eventual effects of long term PKCθ inhibition should also be investigated
in the future. Although the possibility that C20 may act also on other
160 V. Marrocco et al. / EBioMedicine 16 (2017) 150–161targets, together with PKCθ, cannot be ruled out, it is noteworthy that
C20 treatment in mdx mostly resembles the phenotype observed
when PKCθ was ablated in mdx mice. Differently from the activity of
other anti-inflammatory agents, given the peculiar, specific, activity of
PKCθ on T cell, its inhibition should result in an immune-modulation
rather than a general immune suppression,making PKCθ a potential tar-
get to reduce the immune response avoiding eventual side effects asso-
ciated with the drugs currently used in clinic.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.01.001.Authors Contributions
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